Literature DB >> 9638793

IV perflubron emulsion versus autologous transfusion in severe normovolemic anemia: effects on left ventricular perfusion and function.

O Habler1, M Kleen, J Hutter, A Podtschaske, M Tiede, G Kemming, M Welte, C Corso, S Batra, P Keipert, S Faithfull, K Messmer.   

Abstract

Intact cardiac compensatory mechanisms are necessary to maintain adequate tissue oxygenation during acute normovolemic hemodilution (ANH). Left ventricular (LV) perfusion, oxygenation and function were analyzed in an experimental whole-body model of profound ANH (Hct 9%) and effectiveness of a perfluorocarbon-based oxygen carrier in maintaining myocardial oxygenation and function was evaluated. A total of 22 anesthetized dogs were hemodiluted to Hct 20% followed by a simulated, controlled blood-loss phase in which dogs were randomized to either: (1) 1:1 exchange of lost blood with autologous red blood cells (RBC-group), (2) 1:1 exchange with a colloid (control-group) and (3) 1:1 exchange with a colloid after a single dose of 1.8 g/kg BW perflubron i.v. (PFC-group). Myocardial oxygen delivery and consumption as well as endocardial perfusion were determined using radioactive microspheres. LV myocardial contractility (LV MC) was assessed from: (1) the relationship between maximum rate of LV pressure increase (LVdp/dtmax) and LV enddiastolic volume (LVEDV) and (2) analysis of the LV endsystolic pressure volume relationship (ESPVR). LV diastolic properties were reflected by (1) minimum rate of LV pressure increase (LVdp/dtmin), (2) slope and intercept of the enddiastolic pressure-volume relationship (EDPVR) and (3) the time-constant of isovolumic LV pressure decline "tau 1/2". Full sets of LV MC data were obtained from 18 dogs (n = 6 per group). LV MC (LVdp/dtmax-LVEDV relation) increased after perflubron administration. At the lowest Hct level, all parameters reflecting LV MC as well as LVdp/dtmin were significantly higher in the PFC-group than in the control-group. After profound normovolemic hemodilution (Hct 9%) superiority of LV MC and LV diastolic properties was found, when myocardial oxygenation was supported by i.v. perflubron emulsion, a temporary O2 carrier.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9638793     DOI: 10.1007/s004330050079

Source DB:  PubMed          Journal:  Res Exp Med (Berl)        ISSN: 0300-9130


  8 in total

Review 1.  [Perioperative management of Jehovah's Witness patients. Special consideration of religiously motivated refusal of allogeneic blood transfusion].

Authors:  O Habler; B Voss
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

Review 2.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

Review 3.  [Artificial oxygen carriers as an alternative to red blood cell transfusion].

Authors:  O Habler; A Pape; J Meier; B Zwissler
Journal:  Anaesthesist       Date:  2005-08       Impact factor: 1.041

4.  Oxygen transport during hemodilution with a perfluorocarbon-based oxygen carrier: effect of altitude and hyperoxia.

Authors:  Tatiana Gardeazábal; Mariana Cabrera; Pedro Cabrales; Marcos Intaglietta; Juan Carlos Briceño
Journal:  J Appl Physiol (1985)       Date:  2008-06-05

Review 5.  Blood substitutes. Artificial oxygen carriers: perfluorocarbon emulsions.

Authors:  D R Spahn
Journal:  Crit Care       Date:  1999-09-24       Impact factor: 9.097

Review 6.  [Tolerance to perioperative anemia. Mechanisms, influencing factors and limits].

Authors:  O Habler; J Meier; A Pape; H Kertscho; B Zwissler
Journal:  Anaesthesist       Date:  2006-11       Impact factor: 1.041

Review 7.  Bench-to-bedside review: latest results in hemorrhagic shock.

Authors:  Martin K Angele; Christian P Schneider; Irshad H Chaudry
Journal:  Crit Care       Date:  2008-07-10       Impact factor: 9.097

8.  [Tolerance to perioperative anemia. Mechanisms, influencing factors and limits].

Authors:  O Habler; J Meier; A Pape; H Kertscho; B Zwissler
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.